Tesamorelin purity and testing: what buyers need to check

Last updated 2026-07-24

Is tesamorelin FDA-approved, and does that mean it's automatically pure?

Yes, tesamorelin is FDA-approved under the brand names Egrifta and Egrifta SV, specifically for reducing excess abdominal fat in HIV-associated lipodystrophy ^[1][2]. That approval covers a narrow indication, adults with HIV and lipodystrophy, not general fat loss, muscle building, or anti-aging use. The phase 3 trials behind approval were double-blind, placebo-controlled, and pooled across two large multicenter studies with safety extension data, which is about as rigorous as drug evidence gets ^[3]. FDA approval means the manufacturer has to prove batch-to-batch consistency, sterility, and stated potency every single time, under Current Good Manufacturing Practice rules enforced through the drug approval process. That's a real purity guarantee, backed by inspections and required testing. But here's the catch. A lot of tesamorelin sold online isn't Egrifta. It's compounded tesamorelin, or peptide sold as "research chemical." Neither of those carries the same guarantee, even if the underlying peptide sequence is chemically identical to what's in the approved product. Purity is a manufacturing and testing question, more than a molecule question.

What does "purity" actually mean for a peptide like tesamorelin?

Purity has a few distinct components, and vendors often blur them together to make a vial sound more rigorously tested than it is. First is chemical purity: what percentage of the material in the vial is actually the correct 44-amino acid tesamorelin sequence, versus truncated peptide fragments, deletion sequences, or synthesis byproducts. This is measured by high-performance liquid chromatography (HPLC), reported as a percentage (98%, 99%, and so on). Second is identity confirmation: proving the molecule really is tesamorelin, not a similar-looking peptide or a mislabeled substitute. Mass spectrometry is the standard tool here, and researchers have specifically worked on methods to detect synthetic GHRH analogs like tesamorelin in biological samples, which tells you the tools to verify identity exist and are actively used in anti-doping and forensic contexts ^[4]. Third is microbiological safety: sterility, endotoxin levels (measured in EU/mL, endotoxin units per milliliter), and absence of bioburden. This matters enormously for an injectable. A peptide can be 99% chemically pure and still be dangerous if it's packaged in a non-sterile environment or contaminated with bacterial endotoxin. A legitimate certificate of analysis (COA) should report all three: HPLC purity percentage, mass spec confirmation of molecular weight, and sterility/endotoxin results. If a seller only shows you a HPLC chromatogram and nothing else, you're missing two-thirds of the picture.

Why is peptide synthesis quality control such a hard problem?

Tesamorelin is a 44-amino acid peptide, which is long by synthetic peptide standards. Longer chains mean more coupling steps, and every coupling step is a chance for a deletion sequence, a truncated fragment, or an unwanted side reaction. This isn't unique to tesamorelin. Chemists working on peptide ligation methods have specifically studied how to join peptide fragments more cleanly at high dilution, precisely because getting long peptides to assemble without junk byproducts is technically difficult ^[5]. That difficulty is exactly why pharmaceutical-grade manufacturing (the kind behind Egrifta) involves validated synthesis routes, in-process testing, and release specifications that a small compounding operation or an unregulated overseas peptide vendor may not replicate. It's also why cost differences between sources are often quality differences in disguise. Cutting synthesis steps, skipping purification passes, or reusing reagents cuts cost and cuts purity at the same time. Recent reviews covering injectable peptide therapy in sports medicine settings have flagged synthesis and purity variability as a core practical concern for physicians considering peptide use outside strict pharmaceutical channels ^[6][7]. That's a signal from clinicians actively working with these compounds, more than a theoretical worry.

What's the difference between compounded tesamorelin and FDA-approved Egrifta?

Egrifta and Egrifta SV are the only FDA-approved tesamorelin products, manufactured under a New Drug Application with fixed formulation, fixed manufacturing site, and required stability and purity testing at every batch ^[1]. Compounded tesamorelin is prepared by a pharmacy under a different legal framework entirely. Under federal law, compounding pharmacies operate under 21 U.S.C. 353a, which allows a licensed pharmacist to prepare a drug for an individual patient based on a valid prescription, using bulk drug substances that meet certain conditions ^[8]. The FDA maintains lists of bulk substances that 503A pharmacies (traditional compounders) and 503B outsourcing facilities (larger-scale compounders registered with FDA) may use, under 21 CFR 216.23 and 216.24 respectively ^[9][10]. The FDA's own guidance page on bulk substances lays out the criteria and the nomination process pharmacies and suppliers go through to get an ingredient onto that list ^[11][12]. Here's the honest nuance: compounding isn't automatically "unsafe" or "fake." A 503B outsourcing facility registered with FDA has to meet CGMP requirements and is subject to FDA inspection. A random 503A pharmacy filling a one-off prescription has less oversight. And a peptide seller with no pharmacy license at all, shipping vials labeled "not for human consumption," has essentially none. Those are three very different risk tiers, and "compounded" gets used to describe all three, which muddies the purity conversation. If you're considering tesamorelin dosage from a compounded source, the pharmacy's licensing tier is worth asking about directly.

How do I read a certificate of analysis (COA) for tesamorelin?

A COA is the document a supplier should hand you (or post publicly) showing lab test results for a specific batch. Here's what a real one contains, and what its absence should tell you. | COA element | What it shows | Red flag if missing |

Does third-party testing actually catch problems, or is it just marketing?

Third-party testing catches real problems when it's done by an independent lab with no financial stake in the result, using validated methods like HPLC and mass spec. It's marketing when a seller's own staff runs a quick purity check and calls it "lab tested" without naming the lab or showing raw data. The distinction matters because peptide identity testing is a genuinely active area of scientific work, not a solved problem you can hand-wave. Researchers studying detection methods for growth hormone releasing hormone analogs (the drug class tesamorelin belongs to) have specifically noted the analytical challenge of distinguishing legitimate GHRH analogs from degraded or substituted material in complex samples ^[4]. If detecting these molecules accurately requires dedicated analytical chemistry research, a vendor's one-line claim of "99% pure, third-party tested" without a named lab or a downloadable report deserves skepticism. What you want to see: the lab's name (searchable, with a real address), the test method (HPLC-UV, LC-MS, whatever they used), and a date that lines up with when your specific batch was made. Vague purity claims with no paper trail are worth exactly nothing.

What happened in the actual tesamorelin trials, and why does trial-grade material matter?

The key evidence for tesamorelin comes from a pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials with safety extension data, the study design FDA required for approval ^[3]. Additional randomized trial data has shown tesamorelin reduces visceral adipose tissue and improves liver enzymes in HIV patients with excess abdominal fat ^[13], and a randomized double-blind multicenter trial specifically evaluated its effects on non-alcoholic fatty liver disease in this population ^[14]. More recent work has looked at tesamorelin's effects in people with HIV on integrase inhibitor regimens ^[15], its impact on fat quality independent of fat quantity changes ^[16], and even neurocognitive outcomes tied to abdominal obesity ^[17]. A 2026 meta-analysis pooling randomized controlled trial data specifically examined body composition, hepatic fat, metabolic, and safety outcomes for tesamorelin as a class ^[18]. Every one of those trials used pharmaceutical-grade material manufactured to a fixed specification. That's the whole point: the safety and efficacy numbers you read about only apply to material that matches what was actually tested. A compounded or gray-market vial with unknown purity, unknown endotoxin load, or a slightly different peptide sequence isn't the same product those trials evaluated, even if the label says "tesamorelin." This is why the evidence base is strong for Egrifta specifically, and much thinner (effectively nonexistent) for whatever purity level a given compounded batch actually contains.

What contamination or quality risks are specific to tesamorelin, versus peptides generally?

Tesamorelin's approved trials documented a specific safety profile: injection site reactions, joint pain, and effects tied to increased IGF-1 from GH stimulation were tracked carefully across the phase 3 program and its extension ^[3][19]. Reviews of tesamorelin's use in HIV-associated lipodystrophy back up this general tolerability profile at the studied dose and formulation ^[20][21][22]. But that safety data describes the approved product tested at controlled doses. It says nothing about what happens if a compounded vial is under-dosed, over-dosed, contaminated with endotoxin, or contains degraded peptide from poor cold-chain handling. Tesamorelin, like most peptides, is not heat-stable and needs consistent refrigeration from manufacture through reconstitution; broader reviews of injectable peptide therapy flag storage and handling as a recurring real-world failure point separate from the initial manufacturing purity ^[7]. Get the reconstitution process wrong, or store a reconstituted vial improperly, and you can degrade even a genuinely pure starting product. So there are really two purity risk windows: the manufacturing purity (was the peptide made correctly and tested honestly), and the handling purity (was it shipped cold, stored cold, reconstituted with the right diluent, and used within its stability window). A buyer can get burned by either one independently.

How does tesamorelin purity testing compare across sourcing options?

What red flags suggest a tesamorelin source is cutting corners on purity?

A few patterns show up repeatedly among lower-quality sources, and they're worth screening for before you buy anything. No named testing lab. If a COA exists but doesn't name the lab, or the lab can't be found with a basic search, treat the document as unverified. Price far below comparable competitors. Peptide synthesis, purification, and sterility testing all cost money. A price that's dramatically lower than other vendors selling the same claimed purity usually means a step got skipped, most often the purification passes that remove truncated sequences, or the sterility/endotoxin testing that catches contamination. "Research use only" labeling on something marketed for injection into a person. This label exists precisely so the seller can dodge the regulatory requirements that would otherwise apply to a human drug product. It is a legal disclaimer, not a quality statement, and its presence alongside human dosing instructions is a contradiction worth noticing. No licensed pharmacist or prescriber in the loop. Legitimate access to tesamorelin, whether Egrifta or compounded, should involve a prescription and a pharmacist accountable to a state board. If you can order a vial with no clinical oversight at all, nobody with professional liability has looked at the product or your suitability for it. Vague or shifting purity claims. "99% pure" repeated across every product on a site, with no batch-specific number, no chromatogram, and no date, is a marketing slogan, not lab data.

What should I actually ask a provider or pharmacy before buying tesamorelin?

Ask for the batch-specific certificate of analysis, not a generic one. Ask which lab performed the testing and whether it's independent of the manufacturer. Ask whether the facility is a registered 503B outsourcing facility or a 503A pharmacy operating under a patient-specific prescription per 21 U.S.C. 353a ^[8]. Ask how the product is shipped (cold chain, with a temperature indicator) and what the stability window is once reconstituted. If you're going the FDA-approved route, this whole conversation simplifies considerably, because Egrifta's manufacturing and testing is handled at the regulatory level before it ever reaches a pharmacy shelf. A tesamorelin provider-reviewed pathway that connects you with a licensed prescriber and a named fulfilling pharmacy removes most of the guesswork described above, because the accountability chain is documented rather than assumed. Tesamorelin Co's provider-reviewed process is built around exactly that kind of accountable sourcing rather than anonymous vial sales.

Is buying cheaper, unverified tesamorelin ever a reasonable trade-off?

Sometimes cost pressure is real, and it's worth being honest about what you're actually trading away, rather than pretending the choice doesn't exist. If you buy a cheaper, unverified vial, you're trading a known, tested, regulator-backed product for an unknown one, on the bet that the seller is honest and competent. Given that tesamorelin is a 44-amino acid peptide with documented synthesis difficulty ^[5], and that even legitimate manufacturers need validated processes to avoid deletion sequences and contamination, that bet isn't a small one. The dose-response and safety data that exist ^[3][13][18] describe the tested product, and they stop applying the moment purity, sterility, or concentration drift from what was studied. My honest read: for a narrow-indication, prescription drug like tesamorelin, the purity conversation isn't really about shaving cost on a commodity. It's about whether you're getting the thing the trials actually tested. If you can't verify that with a real COA and a real pharmacy behind it, you're not really buying tesamorelin as a known quantity anymore. You're buying a peptide that might be tesamorelin, at a purity nobody has confirmed, from someone with no license on the line.

Frequently asked questions

Is compounded tesamorelin the same as FDA-approved Egrifta?

No. Egrifta and Egrifta SV are the only FDA-approved tesamorelin products, made under a fixed, inspected manufacturing process. Compounded tesamorelin is prepared under a separate legal framework (21 U.S.C. 353a) with variable oversight depending on whether the pharmacy is a 503A compounder or a 503B outsourcing facility, and purity assurance depends entirely on that specific pharmacy's practices.

What purity percentage should tesamorelin have?

Pharmaceutical peptide purity is typically reported by HPLC as a percentage, often 98% or higher for legitimate synthesis. But a percentage alone isn't proof; it needs to come with a batch-specific certificate of analysis from a named, independent lab, plus mass spectrometry identity confirmation and sterility/endotoxin testing, more than a chromatogram.

How can I tell if my tesamorelin vial is contaminated?

You generally can't tell by looking. Contamination (bacterial endotoxin, incorrect peptide fragments) requires lab testing to detect, specifically endotoxin assays and mass spectrometry. This is why a certificate of analysis from the actual batch you're holding matters more than visual inspection, cloudiness, or trusting a seller's marketing claims.

What is a certificate of analysis (COA) and why does it matter for tesamorelin?

A COA is a lab document reporting a specific batch's test results: HPLC purity percentage, mass spec confirmation of identity, and sterility/endotoxin results. It matters because it's the only real evidence tying quality claims to the actual vial you're buying, rather than a generic marketing statement reused across every product listing.

Does FDA approval guarantee every tesamorelin vial is pure?

FDA approval of Egrifta/Egrifta SV means the manufacturer must meet Current Good Manufacturing Practice standards and pass FDA inspection for every batch, which is a strong purity guarantee. It does not extend to compounded or unregulated tesamorelin sold under the same generic name; those require separate verification.

What's the difference between a 503A and 503B compounding pharmacy?

A 503A pharmacy compounds a drug for an individual patient under a specific prescription, with oversight mainly from the state pharmacy board. A 503B outsourcing facility is registered with the FDA, must follow CGMP, and is subject to FDA inspection. Both operate under bulk substance lists defined in 21 CFR 216.23 and 216.24, but 503B carries more federal oversight.

Why is tesamorelin hard to synthesize purely?

Tesamorelin is a 44-amino acid peptide, which is long for synthetic peptide chemistry. Each coupling step in synthesis is a chance for truncated fragments or deletion sequences to form, and researchers have specifically studied better ligation methods to reduce these byproducts in long peptide synthesis, showing that getting it right takes validated, careful processing.

Can peptide testing actually distinguish tesamorelin from a fake or degraded version?

Yes, mass spectrometry and HPLC can confirm both identity and purity, and researchers have developed methods specifically to detect synthetic GHRH analogs like tesamorelin in complex samples for anti-doping and forensic purposes. The tools exist; the question is whether your specific vendor actually used them on your specific batch.

Is 'research use only' tesamorelin safe to inject?

That labeling exists to avoid regulatory requirements that apply to human drug products, not to indicate a quality or safety standard. Research-only vials typically lack sterility testing, verified purity documentation, and any prescriber oversight. Using them for human injection carries meaningfully higher risk than a prescribed, pharmacy-dispensed product.

What tests should a legitimate tesamorelin COA include?

A complete COA should show HPLC purity percentage, mass spectrometry confirmation of molecular identity, sterility testing results, and endotoxin levels in EU/mL, all tied to a specific batch or lot number and performed by a named, independent lab, not the seller's in-house equipment.

Does storage and handling affect tesamorelin purity after purchase?

Yes. Tesamorelin requires consistent refrigeration and proper reconstitution technique. Even a genuinely pure product can degrade if the cold chain is broken during shipping or storage, or if it's reconstituted with the wrong diluent or used past its stability window. Purity testing on the original batch doesn't guarantee quality at the point of injection if handling was poor.

Why does off-label tesamorelin use matter for the purity conversation?

Egrifta's approval and its supporting phase 3 trial data cover HIV-associated lipodystrophy specifically. Off-label use for general fat loss or anti-aging isn't backed by that same trial evidence, and off-label demand is exactly what drives much of the compounded and gray-market supply where purity oversight is weakest.

Sources

1. PubMed, Tesamorelin (2019 review): Tesamorelin is FDA-approved under the brand names Egrifta/Egrifta SV for HIV-associated lipodystrophy
2. PubMed, Tesamorelin (Nature Reviews Drug Discovery, 2011): Tesamorelin's approved indication is reducing excess abdominal fat in HIV-associated lipodystrophy
3. PubMed, pooled phase 3 trial analysis (J Clin Endocrinol Metab, 2010): Approval was based on a pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials with safety extension data
4. PubMed, Advances in the detection of GHRH synthetic analogs (Drug Test Anal, 2021): Detection methods for synthetic GHRH analogs like tesamorelin are an active area of analytical chemistry research
5. PubMed, Peptide Ligation at High Dilution via Reductive Diselenide-Selenoester Ligation (JACS, 2020): Joining long peptide chains cleanly without byproducts is a documented technical challenge in peptide chemistry
6. PubMed, Therapeutic Peptides in Orthopaedics (JAAOS Global Res Rev, 2026): Reviews of therapeutic peptides in orthopaedic and sports medicine settings note synthesis and quality control challenges
7. PubMed, Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (Am J Sports Med, 2026): Storage, handling, and purity variability are flagged as practical concerns for physicians using injectable peptides
8. Cornell Law School, 21 U.S.C. 353a: Federal law allows licensed pharmacists to compound drugs for individual patients under specific conditions
9. eCFR, 21 CFR 216.23 (503A Bulks List): Defines the bulk drug substances list that 503A compounding pharmacies may use
10. eCFR, 21 CFR 216.24 (503B Bulks List): Defines the bulk drug substances list that 503B outsourcing facilities may use
11. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA guidance describes the criteria and process for bulk substances used in 503A compounding
12. FDA, Bulk Drug Substances Nominated for Use in Compounding: FDA maintains a current list of bulk drug substances nominated for compounding use
13. PubMed, Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV (AIDS, 2017): Randomized trial data shows tesamorelin reduces visceral adipose tissue and improves liver enzymes
14. PubMed, Effects of tesamorelin on non-alcoholic fatty liver disease in HIV (Lancet HIV, 2019): A randomized, double-blind, multicentre trial evaluated tesamorelin's effect on NAFLD in HIV patients
15. PubMed, Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors (AIDS, 2024): A study examined tesamorelin outcomes specifically in patients on integrase inhibitor regimens
16. PubMed, Tesamorelin improves fat quality independent of changes in fat quantity (AIDS, 2021): Tesamorelin affects fat quality independently of changes in fat quantity
17. PubMed, Effects of Tesamorelin on Neurocognitive Impairment (J Infect Dis, 2025): A study evaluated tesamorelin's effects on neurocognitive impairment in people with HIV and abdominal obesity
18. PubMed, Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin (Obes Res Clin Pract, 2026): A meta-analysis of randomized controlled trials examined tesamorelin's body composition, hepatic fat, and safety outcomes
19. PubMed, Effects of tesamorelin on inflammatory markers (AIDS, 2011): Trial data tracked inflammatory markers and their relationship to visceral fat reduction with tesamorelin
20. PubMed, Tesamorelin: a review of its use in HIV-associated lipodystrophy (Drugs, 2011): Reviews summarize tesamorelin's tolerability profile in HIV-associated lipodystrophy
21. PubMed, Tesamorelin: a growth hormone-releasing factor analogue (Ann Pharmacother, 2012): Reviews tesamorelin's mechanism and use as a GHRH analogue for HIV-associated lipodystrophy
22. PubMed, Spotlight on tesamorelin in HIV-associated lipodystrophy (BioDrugs, 2011): Summarizes tesamorelin's clinical profile and safety findings in HIV-associated lipodystrophy